Emmi Jokinen

Emmi Jokinen

Auto-generated profile, based on publicly available information

Emmi Jokinen

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
EJEmmi Jokinen
Emmi Jokinen
JHJani Huuhtanen
Jani Huuhtanen
SMSatu Mustjoki
Satu Mustjoki
MHMarkus Heinonen
Markus Heinonen
HLHarri Lähdesmäki
Harri Lähdesmäki
Adaptive immune system uses T cell receptors (TCRs) to recognize pathogens and to consequently initiate immune responses. TCRs can be sequenced from individuals and methods analyzing the specificity of the TCRs can help us better understand individuals’ immune status in different disorders. For this task, we have developed TCRGP, a novel Gaussian process method that predicts if TCRs recognize specified epitopes. TCRGP can utilize the amino acid sequences of the complementarity determining regions (CDRs) from TCRα and TCRβ chains and learn which CDRs are important in recognizing different epitopes. Our comprehensive evaluation with epitope-specific TCR sequencing data shows that TCRGP achieves on average higher prediction accuracy in terms of AUROC score than existing state-of-the-art methods in epitope-specificity predictions. We also propose a novel analysis approach for combined single-cell RNA and TCRαβ (scRNA+TCRαβ) sequencing data by quantifying epitope-specific TCRs with TCRGP and identify HBV-epitope specific T cells and their transcriptomic states in hepatocellular carcinoma patients.

15 March 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JHJani Huuhtanen
Jani Huuhtanen
HKHenna H.E. Kasanen
Henna H.E. Kasanen
KPKatriina Peltola
Katriina Peltola
TLTapio Lönnberg
Tapio Lönnberg
VGVirpi Glumoff
Virpi Glumoff
SMSatu Mustjoki
Satu Mustjoki
BACKGROUND. Relatlimab+nivolumab (anti-LAG3+anti-PD1) has been approved by FDA as a 1st-line therapy in stage III/IV melanoma, but its detailed effect on the immune system is unknown. METHODS. We evaluated blood samples from 40 immunotherapy-naïve or prior immunotherapy-refractory patients with metastatic melanoma treated with anti-LAG3+anti-PD1 in a phase I trial (NCT01968109) using single-cell RNA and T cell receptor (TCR) sequencing (scRNA+TCRαβ-seq) combined with other multiomics profiling. RESULTS. The highest LAG3 expression was noted in NK cells, regulatory T cells (Tregs), and CD8+ T cells, and these cell populations underwent the most significant changes during the treatment. Adaptive NK cells were enriched in responders and underwent profound transcriptomic changes during the therapy resulting in an active phenotype. LAG3+ Tregs expanded but based on the transcriptome profile became metabolically silent during the treatment. Lastly, higher baseline TCR clonality was observed in responding patients, and their expanding CD8+ T cell clones gained more cytotoxic and NK-like phenotype. CONCLUSION. Anti-LAG3+anti-PD1 therapy has profound effects on NK cells and Tregs in addition to CD8+ T cells. TRIAL REGISTRATION. ClinicalTrials.gov (NCT01968109) FUNDING. Cancer Foundation Finland, Sigrid Juselius Foundation, Signe and Ane Gyllenberg Foundation, Relander Foundation, State funding for university-level health research in Finland, a Helsinki Institute of Life Sciences Fellow grant, Academy of Finland, and an investigator-initiated research grant from BMS.

27 June 2018 in Bioinformatics
Verified
Journal Article
Open access
PDF file
EJEmmi Jokinen
Emmi Jokinen
MHMarkus Heinonen
Markus Heinonen
HLHarri Lähdesmäki
Harri Lähdesmäki
Proteins are commonly used by biochemical industry for numerous processes. Refining these proteins’ properties via mutations causes stability effects as well. Accurate computational method to predict how mutations affect protein stability is necessary to facilitate efficient protein design. However, accuracy of predictive models is ultimately constrained by the limited availability of experimental data. We have developed mGPfusion, a novel Gaussian process (GP) method for predicting protein’s stability changes upon single and multiple mutations. This method complements the limited experimental data with large amounts of molecular simulation data. We introduce a Bayesian data fusion model that re-calibrates the experimental and in silico data sources and then learns a predictive GP model from the combined data. Our protein-specific model requires experimental data only regarding the protein of interest and performs well even with few experimental measurements. The mGPfusion models proteins by contact maps and infers the stability effects caused by mutations with a mixture of graph kernels. Our results show that mGPfusion outperforms state-of-the-art methods in predicting protein stability on a dataset of 15 different proteins and that incorporating molecular simulation data improves the model learning and prediction accuracy. Software implementation and datasets are available at github.com/emmijokinen/mgpfusion. Supplementary data are available at Bioinformatics online.

1 December 2023 in Bioinformatics
Verified
Journal Article
Open access
PDF file
DKDani Korpela
Dani Korpela
EJEmmi Jokinen
Emmi Jokinen
ADAlexandru Dumitrescu
Alexandru Dumitrescu
JHJani Huuhtanen
Jani Huuhtanen
SMSatu Mustjoki
Satu Mustjoki
HLHarri Lähdesmäki
Harri Lähdesmäki
T cells play an essential role in adaptive immune system to fight pathogens and cancer but may also give rise to autoimmune diseases. The recognition of a peptide–MHC (pMHC) complex by a T cell receptor (TCR) is required to elicit an immune response. Many machine learning models have been developed to predict the binding, but generalizing predictions to pMHCs outside the training data remains challenging. We have developed a new machine learning model that utilizes information about the TCR from both α and β chains, epitope sequence, and MHC. Our method uses ProtBERT embeddings for the amino acid sequences of both chains and the epitope, as well as convolution and multi-head attention architectures. We show the importance of each input feature as well as the benefit of including epitopes with only a few TCRs to the training data. We evaluate our model on existing databases and show that it compares favorably against other state-of-the-art models. https://github.com/DaniTheOrange/EPIC-TRACE.

7 December 2022 in Bioinformatics
Verified
Journal Article
Open access
PDF file
EJEmmi Jokinen
Emmi Jokinen
ADAlexandru Dumitrescu
Alexandru Dumitrescu
JHJani Huuhtanen
Jani Huuhtanen
VGVladimir Gligorijević
Vladimir Gligorijević
SMSatu Mustjoki
Satu Mustjoki
HLHarri Lähdesmäki
Harri Lähdesmäki
T cells use T cell receptors (TCRs) to recognize small parts of antigens, called epitopes, presented by major histocompatibility complexes. Once an epitope is recognized, an immune response is initiated and T cell activation and proliferation by clonal expansion begin. Clonal populations of T cells with identical TCRs can remain in the body for years, thus forming immunological memory and potentially mappable immunological signatures, which could have implications in clinical applications including infectious diseases, autoimmunity and tumor immunology. We introduce TCRconv, a deep learning model for predicting recognition between TCRs and epitopes. TCRconv uses a deep protein language model and convolutions to extract contextualized motifs and provides state-of-the-art TCR-epitope prediction accuracy. Using TCR repertoires from COVID-19 patients, we demonstrate that TCRconv can provide insight into T cell dynamics and phenotypes during the disease. TCRconv is available at https://github.com/emmijokinen/tcrconv. Supplementary data are available at Bioinformatics online.

6 February 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
EJEmmi Jokinen
Emmi Jokinen
JHJani Huuhtanen
Jani Huuhtanen
SMSatu Mustjoki
Satu Mustjoki
MHMarkus Heinonen
Markus Heinonen
HLHarri Lähdesmäki
Harri Lähdesmäki
T cell receptors (TCRs) can recognize various pathogens and consequently start immune responses. TCRs can be sequenced from individuals and methods analyzing the specificity of the TCRs can help us better understand individuals’ immune status in different diseases. We have developed TCRGP, a novel Gaussian process method to predict if TCRs recognize certain epitopes. This method can utilize CDR sequences from TCR α and TCR β chains and learn which CDRs are important in recognizing different epitopes. We have experimented with with epitope-specific data against 29 epitopes and performed a comprehensive evaluation with existing prediction methods. On this data, TCRGP outperforms other state-of-the-art methods in epitope-specificity predictions. We also propose a novel analysis approach for combined single-cell RNA and TCR αβ (scRNA+TCR αβ ) sequencing data by quantifying epitope-specific TCRs with TCRGP in phenotypes identified from scRNA-seq data. With this approach, we find HBV-epitope specific T cells and their transcriptomic states in hepatocellular carcinoma patients.